Reviewing ZIVO Bioscience (NASDAQ:ZIVO) and Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences (NASDAQ:NBIX) and ZIVO Bioscience (NASDAQ:ZIVO) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Institutional and Insider Ownership

92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 4.4% of Neurocrine Biosciences shares are held by company insiders. Comparatively, 13.4% of ZIVO Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Neurocrine Biosciences and ZIVO Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	13.23%	12.85%	9.02%
ZIVO Bioscience	N/A	N/A	-691.99%

Valuation and Earnings

This table compares Neurocrine Biosciences and ZIVO Bioscience’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$1.89 billion	7.26	$249.70 million	$2.42	56.93
ZIVO Bioscience	$30,000.00	746.67	-$7.78 million	($4.59)	-1.74

Neurocrine Biosciences has higher revenue and earnings than ZIVO Bioscience. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Neurocrine Biosciences has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500. Comparatively, ZIVO Bioscience has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Neurocrine Biosciences and ZIVO Bioscience, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0	6	17	0	2.74
ZIVO Bioscience	0	0	0	0	N/A

Neurocrine Biosciences presently has a consensus target price of $142.38, suggesting a potential upside of 3.35%. Given Neurocrine Biosciences’ higher probable upside, research analysts plainly believe Neurocrine Biosciences is more favorable than ZIVO Bioscience.

Summary

Neurocrine Biosciences beats ZIVO Bioscience on 11 of the 13 factors compared between the two stocks.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

About ZIVO Bioscience

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.